SCOTS shows that vision loss in Retinitis Pigmentosa can be improved.
After over 5 years of clinical research and patient treatment, 0ur peer-reviewed journal publication reveals RP does not need to lead to blindness.
The results are statistically significant – the ‘gold standard’ for medical and scientific work- as documented by an independent, university statistician
What did the report show?
- 64.7% of patients showed improved visual acuity using both eyes.
- 45.5% of eyes showed improved vision; 45.5% remained stable over the follow up
- Benefited eyes averaged a 40.9% improvement in vision
- There were no complications or adverse events- meaning the treatment was safe
Weiss JN, Levy S. Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of Retinitis Pigmentosa. Stem Cell Investigation June 2018
RP paper Abstract with Results: Following therapy in SCOTS or SCOTS 2, 11
patients (64.7%) showed improved binocular vision averaging 10.23 lines
of Snellen acuity per eye over pre-treatment acuity; 8 patients (35.3%)
remaining stable over the follow up period; no patients experiencing
loss of overall acuity. In 33 treated eyes, 15 eyes (45.5%) improved an
average of 7.9 lines of Snellen acuity, 15 eyes (45.5%) remained stable,
and 3 eyes (9%) worsened by an average of 1.7 lines of Snellen acuity.
Improvements ranged from 1 to 27 lines of vision. Using the LogMAR Scale
and calculating delta as a ratio to pre-treatment vision in improved
eyes, acuity improvement ranged from 23% to 90% with an average of 40.9%
visual acuity improvement over baseline vision. Evaluation of all
patients and eyes capable of LogMAR vision showed an average of 31%
improvement in vision over baseline. Findings were of statistical
significance (P=0.016). There were no surgical complications.